The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GNPX | -84.77% | -99.83% | -72.03% | -93% |
| S&P | +15.06% | +95.03% | +14.29% | +155% |
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $330.55M | 67.1% |
| Market Cap / Employee | $22.04M | 0.0% |
| Employees | 15 | 0.0% |
| Net Income | -$4.67M | 28.0% |
| EBITDA | -$4.68M | 28.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.35M | -45.2% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -331.39% | -99.2% |
| Return On Invested Capital | -386.77% | -190.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.86M | 33.3% |
| Operating Free Cash Flow | -$3.86M | 33.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 10.64 | 140.38 | 82.22 | 71.16 | 243.89% |
| Price to Tangible Book Value | 10.64 | 140.38 | 82.22 | 71.16 | 212.84% |
| Enterprise Value to EBITDA | 0.05 | -1.76 | -0.07 | -1.06 | 325.54% |
| Return on Equity | -325.1% | -467.2% | -302.7% | -602.6% | 88.99% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
